BioSpace News Archive

Thomas M. Kaiser, MD, PhD, is the co-founder and chief scientific officer at Avicenna Biosciences. He founded Avicenna with Pieter Burger in 2019.

Pictured: Front view of the CDC museum in Georgia

Vaccines

CDC Vaccine Advisory Board Meeting Postponed Days After RFK Jr. Confirmation

The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human Services, despite controversy regarding his anti-vaccine history.

February 21, 2025

·

2 min read

·

Tristan Manalac

Photo of a GLP-1 injector pen on a blue background

GLP-1s

Coalition Urges FDA to Act as Report Finds Illegal GLP-1 Ingredients ‘Flooding’ Into US

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis. Separately, a group of state attorneys general has raised concerns about the unsafe GLP-1 drugs finding their way to American consumers.

February 21, 2025

·

4 min read

·

Tristan Manalac

Mergers & acquisitions

Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M

The proposed acquisition by global investment firms Carlyle and SK Capital Partners could net shareholders $3 per share plus potential CVR dollars and provide bluebird bio with primary capital to expand the commercial reach of its gene therapies.

February 21, 2025

·

3 min read

·

Heather McKenzie

Signage at Pfizer's world headquarters in New York City

Gene therapy

Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

February 21, 2025

·

2 min read

·

Tristan Manalac

Digital collage modern art. Hands reaching together and shaking, with loading icon

Mergers & acquisitions

Concentra Offers to Buy Acelyrin, Endangering Proposed Merger With Alumis

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding the combined company over until 2027.

February 21, 2025

·

2 min read

·

Tristan Manalac

Press Releases

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

February 21, 2025

·

10 min read

Press Releases

FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease